BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 22370122)

  • 1. Overcoming regulatory and economic challenges facing pharmacogenomics.
    Cohen JP
    N Biotechnol; 2012 Sep; 29(6):751-6. PubMed ID: 22370122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and economic challenges facing pharmacogenomics.
    Cohen J; Wilson A; Manzolillo K
    Pharmacogenomics J; 2013 Aug; 13(4):378-88. PubMed ID: 22231566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Personalized medicine and rescuing "unsafe" drugs with pharmacogenomics: a regulatory perspective.
    Avery M
    Food Drug Law J; 2010; 65(1):37-65, i-ii. PubMed ID: 24475534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Companion diagnostics and reimbursement system].
    Tazawa Y
    Rinsho Byori; 2013 May; 61(5):435-42. PubMed ID: 23947184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Personalized medicine policy challenges: measuring clinical utility at point of care.
    van Rooij T; Wilson DM; Marsh S
    Expert Rev Pharmacoecon Outcomes Res; 2012 Jun; 12(3):289-95. PubMed ID: 22812553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Personalized medicine: elusive dream or imminent reality?
    Lesko LJ
    Clin Pharmacol Ther; 2007 Jun; 81(6):807-16. PubMed ID: 17505496
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pharmacogenomics].
    Nakatani K; Nobori T
    Rinsho Byori; 2013 Nov; 61(11):1018-25. PubMed ID: 24450107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Payers and the assessment of clinical utility for companion diagnostics.
    Quinn B
    Clin Pharmacol Ther; 2010 Dec; 88(6):751-4. PubMed ID: 21081944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ethics and policy perspectives on personalized medicine in the post-genomic era.
    Landon MR
    J Biolaw Bus; 2005; 8(3):28-36. PubMed ID: 16459425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Do companion diagnostics make economic sense for drug developers?
    Agarwal A
    N Biotechnol; 2012 Sep; 29(6):695-708. PubMed ID: 22575210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The promise of pharmacogenetics: assessing the prospects for disease and patient stratification.
    Smart A; Martin P
    Stud Hist Philos Biol Biomed Sci; 2006 Sep; 37(3):583-601. PubMed ID: 16980196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Companion diagnostics: significances and issues in its clinical application].
    Miyachi H
    Rinsho Byori; 2011 Jun; 59(6):602-9. PubMed ID: 21815484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Implications of pharmacogenomics for drug development and clinical practice.
    Ginsburg GS; Konstance RP; Allsbrook JS; Schulman KA
    Arch Intern Med; 2005 Nov; 165(20):2331-6. PubMed ID: 16287761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating the value of genomic diagnostics: implications for clinical practice and public policy.
    Issa AM
    Adv Health Econ Health Serv Res; 2008; 19():191-206. PubMed ID: 19548519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation, reimbursement, and the long road of implementation of personalized medicine--a perspective from the United States.
    Frueh FW
    Value Health; 2013; 16(6 Suppl):S27-31. PubMed ID: 24034309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. US FDA perspective on challenges in co-developing in vitro companion diagnostics and targeted cancer therapeutics.
    Philip R; Carrington L; Chan M
    Bioanalysis; 2011 Feb; 3(4):383-9. PubMed ID: 21338257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Discussing the usefulness of companion diagnostics - introductory remarks by chairpersons].
    Nobori T; Nomura F
    Rinsho Byori; 2014 Dec; 62(12):1263-4. PubMed ID: 25823244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Personalized medicine and the role of health economics and outcomes research: issues, applications, emerging trends, and future research.
    O'Donnell JC
    Value Health; 2013; 16(6 Suppl):S1-3. PubMed ID: 24034305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Translation of pharmacogenomics and pharmacogenetics: a regulatory perspective.
    Lesko LJ; Woodcock J
    Nat Rev Drug Discov; 2004 Sep; 3(9):763-9. PubMed ID: 15340386
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Quantitative Assessment of Factors Affecting the Technological Development and Adoption of Companion Diagnostics.
    Luo D; Smith JA; Meadows NA; Schuh A; Manescu KE; Bure K; Davies B; Horne R; Kope M; DiGiusto DL; Brindley DA
    Front Genet; 2015; 6():357. PubMed ID: 26858745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.